MagPortal.com   Clustify - document clustering
 Home  |  Newsletter  |  My Articles  |  My Account  |  Help 
Similar Articles
Bio-IT World
February 2007
Kevin Davies
Ten Years After: Learn and Confirm Wyeth faces the same problems bedeviling the industry: the soaring cost of development is matched only by the rising attrition rate as once promising drug candidates fall by the wayside. But a new strategy leads to a more science-driven model. mark for My Articles similar articles
Pharmaceutical Executive
July 1, 2006
Derek Lowe
What You Need to Know About Adaptive Trials A handful of new statistical techniques and clinical-trial designs will let you change the way you run your business. Here's your guide to the basics. mark for My Articles similar articles
Pharmaceutical Executive
June 9, 2014
Getz et al.
Adaptive Trial Design: Prepping for Adoption Biopharmaceutical companies are targeting improvements in clinical trial design as a critical factor in pipeline portfolio success. mark for My Articles similar articles
Pharmaceutical Executive
January 1, 2006
Clinton & Wechsler
What Ever Happened to Critical Path FDA's ambitious program to improve drug development disappeared from view almost as soon as it was announced. Suddenly, it's back, but is it here to stay? mark for My Articles similar articles
Pharmaceutical Executive
July 1, 2012
William Looney
Today's Mission Critical: Making Sense of Spending on Clinical Trials Mastery of the clinical trial process has become essential to positioning new therapies for leadership in an increasingly crowded and lengthy race to registration. mark for My Articles similar articles
Bio-IT World
June 2006
Mark D. Uehling
Real-Time Trials Currently, there is more visibility into the precise location of a FedEx package than the progress of a multimillion-dollar clinical drug trial. But adaptive design trials are changing that. mark for My Articles similar articles
Chemistry World
October 15, 2013
Dinsa Sachan
Supreme court ruling brings clinical trials to a halt in India The fate of 162 global clinical trials hangs in the balance, as the top Indian court has asked the government to provide more details on their approval process before they can proceed. mark for My Articles similar articles
Pharmaceutical Executive
December 1, 2010
Walter Armstrong
Alzheimer's: A Disease at a Crossroads The need for new drugs intensifies as more and more Baby Boomers live into advanced old age. The global market is estimated to be worth $20 billion by the end of the decade. mark for My Articles similar articles
Bio-IT World
August 13, 2002
Mark D. Uehling
Clinical Trial Data Management: Tortured by Paper Reams of paper stuffed into boxes and shipped to the FDA by the truckload is hardly the best approach to drug approval. But what's the right way? mark for My Articles similar articles
The Motley Fool
May 17, 2010
Luke Timmerman
Vertex Awaits Final Proof that Hepatitis C Drug Works For this drug researcher, the proof is in the telaprevir. mark for My Articles similar articles
Reason
Aug/Sep 2007
Kerry Howley
Dying for Lifesaving Drugs Will desperate patients destroy the pharmaceutical system that produces tomorrow's treatments? mark for My Articles similar articles
The Motley Fool
March 1, 2007
Brian Lawler
Know Your Drug Stock ABCs: Part 2 Investing in the pharmaceutical and biotechnology industries can be difficult. Here are terms investors should know to better understand how the clinical trial process involved with bringing a drug to market works. mark for My Articles similar articles
BusinessWeek
February 6, 2006
Amy Barrett
Cracking The Whip At Wyeth Wyeth's R&D chief Robert Ruffolo imposed tough targets on scientists - and it's working. mark for My Articles similar articles
Investment Advisor
December 2005
Greg B. Scott
Buying The Future Prudent investing in biotechnology can offer great returns for clients. It's also the wave of the future. Armed with a basic understanding of the dynamics of the industry and the valuation inflection points, intelligent investors can make significant returns. mark for My Articles similar articles
Chemistry World
September 2007
Derek Lowe
Column: In the Pipeline Will Phase Zero trials actually help drug development? mark for My Articles similar articles
Pharmaceutical Executive
November 1, 2012
Sue Barrowcliffe
Real World Insights Commercial teams as well as patients can benefit from managed access programs, which are designed to provide access to medicines outside of the clinical and commercial setting, for patients who have no other available treatment options. mark for My Articles similar articles
Bio-IT World
March 2006
Kevin Davies
Clinical Data Launches Landmark Trial Clinical Data has launched a Phase III clinical trial for the depression drug vilazodone and will concurrently develop a diagnostic test. The study could prove to be a landmark event in pharmacogenomic medicine. mark for My Articles similar articles
The Motley Fool
July 27, 2010
Jim Mueller
3 Stocks to Play Biotech Here are three promising ideas for this exciting area. mark for My Articles similar articles
The Motley Fool
March 3, 2010
Brian Orelli
A Costly Missed Connection Dimebon's phase 3 failure costs Medivation shareholders 67%. mark for My Articles similar articles
The Motley Fool
May 31, 2011
Brian Orelli
5 Biotechs With Upcoming Clinical Trial Results Investors willing to stay in these stocks a little while could see substantial gains well ahead of FDA approvals. mark for My Articles similar articles
Pharmaceutical Executive
December 1, 2010
Walter Armstrong
The Next Wave: Pharm Exec's 2011 Pipeline Report 42 of the best new drugs in development or parked at the FDA mark for My Articles similar articles
Chemistry World
November 2010
Column: In the Pipeline Should drug companies focus on big markets and the blockbuster dream? mark for My Articles similar articles
The Motley Fool
January 3, 2011
Brian Orelli
Clinical Trial Results Fail to Inspire Inspire Pharma gets cut in half after a cystic fibrosis trial failure. mark for My Articles similar articles
Pharmaceutical Executive
December 1, 2010
The Sum of All His Parts: Career Reflections of Europe's Chief Drug Regulator The European Medicines Agency is a unique institution, pursuing a mandate shared with a complex web of national and regional groups, each able to place a distinctive imprint around the delicate task of certifying the safety and efficacy of new drugs. mark for My Articles similar articles
Pharmaceutical Executive
June 1, 2014
Jill Wechsler
Compassionate Use Requests Complicate Drug Development Pharma, HCPs, and regulators walk tightrope in addressing early-access push while supporting biomedical R&D. mark for My Articles similar articles
Pharmaceutical Executive
May 1, 2007
Weiner & Hovde
Critical Mass for Critical Path? Everyone agrees that it's the road to pharma's future, but no one's rushing to take it. Yet with growing FDA advocacy and new advances in biomarkers and drug-disease modeling, the rewards of collaboration now look greater than the risks. mark for My Articles similar articles
The Motley Fool
December 27, 2010
Brian Orelli
Painful Clinical Hold? Not Really. Regeneron offers the benefits of a full pipeline. mark for My Articles similar articles
Fast Company
December 2009
Erica Westly
The Price of Winning FDA Approval Approval for a new drug or medical treatment requires extensive -- and expensive -- human trials for safety and effectiveness. mark for My Articles similar articles
Pharmaceutical Executive
August 1, 2013
William Looney
Breaching the Great Wall With a revision of China's basic drug approval law now underway, a multinational team of experts is proposing major changes to make the country a world class player in innovation. mark for My Articles similar articles
Pharmaceutical Executive
October 1, 2005
Lisa Grimes
Clear Road Ahead An industry standard for publicizing clinical-trial results is a ways off. But pharma's openness to more transparent procedures is moving things in the right direction. mark for My Articles similar articles
Pharmaceutical Executive
June 1, 2012
2012 Dealmakers Outlook With Yankee Stadium as the backdrop, Pharm Exec convened on its annual panel of heavy hitters in business development to crack the bat on best practices in licensing and for the year ahead. mark for My Articles similar articles
The Motley Fool
June 18, 2008
Brian Lawler
Elan's and Wyeth's Data: Success or Failure? Elan and partner Wyeth released new mid-stage data for their potential blockbuster bapineuzumab (AAB-001) for Alzheimer's disease, but the results aren't conclusive. mark for My Articles similar articles
The Motley Fool
May 19, 2010
Brian Orelli
The Biggest-Little Biotechs in the World If you do decide to invest in these biotechs before they've secured phase 3 results make sure you know what you're getting yourself into and aren't blindly following the crowd. mark for My Articles similar articles
Pharmaceutical Executive
October 1, 2008
RS Kumar
Evolving Clinical Trials Clinical trials need to change. A recent survey shows that industry should address the research supply chain for the greatest gains in efficiency. mark for My Articles similar articles
Wired
March 2006
Jennifer Kahn
A Nation of Guinea Pigs There's a new outsourcing boom in South Asia - and a billion people are jockeying for the jobs. How India became the global hot spot for drug trials. mark for My Articles similar articles
Pharmaceutical Executive
November 1, 2013
Roundtable on Market Access Market Access is a window on what matters in the real world of soaring patient expectations and crimped payer budgets for innovation. mark for My Articles similar articles
The Motley Fool
September 7, 2010
Luke Timmerman
Vertex Nails Third Big Trial With Hepatitis C Drug And in the toughest patients to treat, too. mark for My Articles similar articles
Bio-IT World
May 9, 2003
Mark D. Uehling
Data Rapture? Electronic capture of data: Some say it unclogs the medieval clinical trials process. Others remain skeptical of software and put their trust in paper. mark for My Articles similar articles
Bio-IT World
April 2006
Kevin Davies
Putting the IT in Clinical Trials A new report says that the clinical trials process must be reinvented to reverse the output decline of the pharmaceutical industry and meet the needs of its patients. That reinvention will be shaped by major advances in information technology. mark for My Articles similar articles
Bio-IT World
August 13, 2003
John Rhodes
Beyond the Blockbuster Genomics and big hits are not mutually exclusive, writes Deloitte & Touche's life sciences expert. mark for My Articles similar articles
The Motley Fool
December 29, 2006
Brian Lawler
Is Threshold on the Verge of Success? Shares of Threshold Pharmaceuticals were the second-best performer on the market yesterday, up 28% as a result of positive phase 2 clinical trial results for its lead drug, glufosfamide. mark for My Articles similar articles
The Motley Fool
January 26, 2005
Stephen D. Simpson
The Pipeline to Biotech Success Looking at drug R&D is the best way to begin assessing biotech companies as possible investment opportunities. mark for My Articles similar articles
The Motley Fool
February 16, 2010
Brian Orelli
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. mark for My Articles similar articles
Bio-IT World
December 15, 2003
Mark D. Uehling
Model Patient Despite the FDA's new support for computational modeling, the pharmaceutical industry remains cautious about simulating clinical trials. mark for My Articles similar articles
The Motley Fool
August 9, 2010
Jim Mueller
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. mark for My Articles similar articles
Chemistry World
January 25, 2013
Rajesh Parishwad
Indian supreme court's anger over unregulated clinical trials The fledgling clinical trials industry in India has been hit by recent revelations of a lack of regulation. Now, the country's supreme court has criticized the body that oversees clinical trials for its inaction in the face of these unethical practices. mark for My Articles similar articles
The Motley Fool
July 1, 2011
Alex Crawford
3 Biotech Drugs With Promising Phase III Data, Moving Into FDA Review Do these drugs have a chance of FDA approval? mark for My Articles similar articles
Bio-IT World
October 2006
William Claypool
The Perfect Circle With the most current technologies accelerating adaptive trial designs, the future holds great promise. mark for My Articles similar articles
The Motley Fool
September 14, 2010
Luke Timmerman
Arena Obesity Drug Effective by "Slim Margin"; Shares Tumble The market is reacting negatively to news about the company's weight-loss drug. mark for My Articles similar articles
The Motley Fool
May 11, 2010
Ryan McBride
Clinical Data Seeks to Challenge Lilly, Pfizer in Antidepressant Market The tiny drug developer has no problem going up against bigger rivals. mark for My Articles similar articles